Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience-Reference-Cited by-同舟云学术

Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience

Published:2011-02 Issue:2 Volume:93 Page:163-169
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Jang Moon Ju,Chong So Young,Kim In-Ho,Kim Jee-Hyun,Jung Chul-Won,Kim Ja Young,Park Ji-Chan,Lee Sun Min,Kim Yeo-Kyeoung,Lee Ji-Eun,Jang Sung-Su,Kim Jin-Seok,Jo Deog-Yeon,Zang Dae-Young,Lee Young-Yiul,Yhim Ho-Young,Oh Doyeun

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-011-0771-5.pdf

Reference26 articles.

1. Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.

2. Moake JL, Turner NA, Stathopoulos NA, Nolasco LH, Hellums JD. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest. 1986;78:1456–61.

3. Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood. 1996;87:4223–34.

4. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–94.

5. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–63.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Features and Relapse/Refractory Disease Risk Factors of Patients with Acquired Thrombotic Thrombocytopenic Purpura in the Western Mediterranean Region of Turkey;OSMANGAZİ JOURNAL OF MEDICINE;2024-07-09

2. IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

3. Should we consider caplacizumab as routine treatment for acute thrombotic thrombocytopenic purpura? An expert perspective on the pros and cons;Expert Review of Hematology;2024-02-20

4. A narrative review of clinical biomarkers predicting outcome of immune-mediated thrombotic thrombocytopenic purpura;Annals of Blood;2023-12

5. Immune thrombotic thrombocytopenic purpura in older patients: Results from the Spanish TTP Registry (REPTT);British Journal of Haematology;2023-09-18